CAS 87805-34-3

glucagon-like peptide I human

Description:

Glucagon-like peptide-1 (GLP-1) is a peptide hormone that plays a crucial role in glucose metabolism and appetite regulation. It is produced in the intestines in response to food intake and is known for its ability to enhance insulin secretion from the pancreas, inhibit glucagon release, and slow gastric emptying, thereby contributing to lower blood glucose levels. The human form of GLP-1, with the CAS number 87805-34-3, consists of 30 amino acids and is characterized by its biological activity, which includes promoting satiety and reducing food intake. Additionally, GLP-1 has neuroprotective effects and is being studied for its potential therapeutic applications in treating type 2 diabetes and obesity. Its stability in the bloodstream is limited due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), leading to the development of GLP-1 receptor agonists that mimic its action while providing longer-lasting effects. Overall, GLP-1 is a vital component of the body's endocrine system, influencing both metabolic and neurological functions.

Formula: C₁₈₆H₂₇₅N₅₁O₅₉

InChI: InChI=1/C186H275N51O59/c1-17-94(10)149(182(294)209-98(14)155(267)220-128(73-105-78-199-111-42-28-27-41-109(105)111)171(283)223-123(68-91(4)5)173(285)234-147(92(6)7)180(292)219-113(43-29-31-63-187)158(270)200-81-136(245)210-112(45-33-65-197-185(191)192)157(269)203-84-146(262)263)236-174(286)126(70-102-37-23-19-24-38-102)225-165(277)120(55-61-142(254)255)216-162(274)114(44-30-32-64-188)212-153(265)96(12)206-152(264)95(11)207-161(273)118(51-57-135(190)244)211-137(246)82-201-160(272)117(53-59-140(250)251)215-168(280)122(67-90(2)3)222-170(282)125(72-104-47-49-108(243)50-48-104)226-177(289)132(85-238)230-179(291)134(87-240)231-181(293)148(93(8)9)235-176(288)131(77-145(260)261)228-178(290)133(86-239)232-184(296)151(100(16)242)237-175(287)127(71-103-39-25-20-26-40-103)229-183(295)150(99(15)241)233-138(247)83-202-159(271)116(52-58-139(248)249)213-154(266)97(13)208-167(279)129(75-107-80-196-89-205-107)227-163(275)115(46-34-66-198-186(193)194)214-164(276)119(54-60-141(252)253)217-169(281)124(69-101-35-21-18-22-36-101)224-166(278)121(56-62-143(256)257)218-172(284)130(76-144(258)259)221-156(268)110(189)74-106-79-195-88-204-106/h18-28,35-42,47-50,78-80,88-100,110,112-134,147-151,199,238-243H,17,29-34,43-46,51-77,81-87,187-189H2,1-16H3,(H2,190,244)(H,195,204)(H,196,205)(H,200,270)(H,201,272)(H,202,271)(H,203,269)(H,206,264)(H,207,273)(H,208,279)(H,209,294)(H,210,245)(H,211,246)(H,212,265)(H,213,266)(H,214,276)(H,215,280)(H,216,274)(H,217,281)(H,218,284)(H,219,292)(H,220,267)(H,221,268)(H,222,282)(H,223,283)(H,224,278)(H,225,277)(H,226,289)(H,227,275)(H,228,290)(H,229,295)(H,230,291)(H,231,293)(H,232,296)(H,233,247)(H,234,285)(H,235,288)(H,236,286)(H,237,287)(H,248,249)(H,250,251)(H,252,253)(H,254,255)(H,256,257)(H,258,259)(H,260,261)(H,262,263)(H4,191,192,197)(H4,193,194,198)/t94-,95-,96-,97-,98-,99?,100?,110-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,147-,148-,149-,150-,151-/m0/s1

SMILES: CC[C@H](C)[C@@H](C(=N[C@@H](C)C(=N[C@@H](Cc1c[nH]c2ccccc12)C(=N[C@@H](CC(C)C)C(=N[C@@H](C(C)C)C(=N[C@@H](CCCCN)C(=NCC(=N[C@@H](CCCNC(=N)N)C(=NCC(=O)O)O)O)O)O)O)O)O)O)N=C([C@H](Cc1ccccc1)N=C([C@H](CCC(=O)O)N=C([C@H](CCCCN)N=C([C@H](C)N=C([C@H](C)N=C([C@H](CCC(=N)O)N=C(CN=C([C@H](CCC(=O)O)N=C([C@H](CC(C)C)N=C([C@H](Cc1ccc(cc1)O)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C(C)C)N=C([C@H](CC(=O)O)N=C([C@H](CO)N=C([C@H](C(C)O)N=C([C@H](Cc1ccccc1)N=C([C@H](C(C)O)N=C(CN=C([C@H](CCC(=O)O)N=C([C@H](C)N=C([C@H](Cc1cnc[nH]1)N=C([C@H](CCCNC(=N)N)N=C([C@H](CCC(=O)O)N=C([C@H](Cc1ccccc1)N=C([C@H](CCC(=O)O)N=C([C@H](CC(=O)O)N=C([C@H](Cc1cnc[nH]1)N)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O

Synonyms:

• Glucagon-like peptide I (1-37)
• Glp-I (1-37)
• Glucagon-related peptide I (ox)
• Glycine, L-histidyl-L-alpha-aspartyl-L-alpha-glutamyl-L-phenylalanyl-L-alpha-glutamyl-L-arginyl-L-histidyl-L-alanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-Llysylglycyl-L-arginyl-
• Glp-1

GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat)

CAS: 87805-34-3

Glucagon-Like Peptide 1 (GLP-1) is synthesized by posttranslational processing of proglucagon in the intestine and pancreas and plays an important role in metabolic homeostasis. Among the different molecular forms, such as GLP-1 (7-36) amide and GLP-1 (7-37), the function of GLP-1 (1-37) has been unclear. GLP-1 (1-37) was shown to convert intestinal epithelial cells into insulin-producing cells. These observations turned GLP-1 (1-37) into a new promising therapeutic compound for the treatment of diabetes mellitus. In animal models of dilated cardiomyopathy, hypertensive heart failure, and myocardial infarction, GLP-1 has shown a remarkable cardioprotective activity.

Formula: C₁₈₆H₂₇₅N₅₁O₅₉

Purity: 97.1%

Color and Shape: White Lyophilisate

Molecular weight: 4169.54

Ref: 01-4037542

Glucagon-like peptide 1 (1-37), human

CAS: 87805-34-3

Human GLP-1 (1-37) is a potent GLP-1 receptor agonist without impact on rat food intake or insulin secretion.

Formula: C₁₈₆H₂₇₅N₅₁O₅₉

Purity: 98%

Color and Shape: Solid

Molecular weight: 4169.48

Ref: TM-TP1148

Glucagon-like peptide I (human)(GLP-I,1-37) Trifluoroacetate

CAS: 87805-34-3

Formula: C₁₈₆H₂₇₅N₅₁O₅₉·C₂HF₃O₂

Molecular weight: 4169.54

Ref: 4Z-PG-194024

HuGLP-1

CAS: 87805-34-3

HuGLP-1

Color and Shape: White Lyophilised Powder

Ref: 54-BITH3020

GLP-1 (1-37)

CAS: 87805-34-3

Glucagon-like peptide (GLP) 1 is a post-translationally modified version of proglucagon. GLP-1 (1-37) is a naturally produced analog of GLP-1. Unlike truncated GLP-1, GLP-1 (1-37) does not alter food intake in rat models or pancreatic insulin secretion. GLP-1 (1-37) can induce insulin production in developing adult intestinal cells via upregulation of the ngn3 gene and its downstream targets. This can restore glucose homeostasis when implanted into diabetic mice. GLP-1 (1-37) may offer a  future treatment for diabetes mellitus. GLP-1 (1-37) can also inhibit chemokine-induced migration of human CD4-positive lymphocytes, an early step in atherogenesis. This raises the possibility that GLP-1 (1-37) is part of a novel mechanism to modulate vascular disease.

Molecular weight: 4,169.54 g/mol

Ref: 3D-CRB1001037

GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat)

CAS: 87805-34-3

Custom research peptide; min purity 95%. For different specs please use the Peptide Quote Tool

Formula: C₁₈₆H₂₇₅N₅₁O₅₉

Molecular weight: 4,169.54 g/mol

Ref: 3D-PP50515

GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt

CAS: 87805-34-3

GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt is a posttranslational modification of the endogenous human hormone GLP-1. It is a synthetic form of this hormone that has been modified to allow for improved stability and solubility. This peptide is found in the pancreatic alpha cells and intestinal L cells and stimulates the release of insulin from pancreatic beta cells. GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt has also been shown to increase glucose uptake by muscle tissue as well as stimulate the release of incretin hormones such as glucagon-like peptide 1 and gastric inhibitory polypeptide. GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt

Formula: C₁₈₆H₂₇₅N₅₁O₅₉

Purity: Min. 95%

Molecular weight: 4,169.48 g/mol

Ref: 3D-FG109540